← All trials
NCT00696475
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Jan 1, 2009
- Completion date
- Mar 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Essentialis, Inc.Lead sponsor
- Meridien ResearchOverall official - principal investigator
- TriCities Medical ResearchOverall official - principal investigator
- Sterling Research Group, LtdOverall official - principal investigator
- Midwest Institute for Clinical ResearchOverall official - principal investigator
- Frederick C. Smith ClinicOverall official - principal investigator
- Jacksonville Center for Clinical ResearchOverall official - principal investigator
- PMG ResearchOverall official - principal investigator
- Allied Research InternationalOverall official - principal investigator
- Medpace, Inc.Collaborator
- L-Marc Research CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.